The precursor homocysteine is metabolized either through the methionine cycle to produce methionine or through the transsulfuration pathway to synthesize cysteine. Alternatively, cysteine can be obtained through uptake of its oxidized form, cystine. Many cancer cells exhibit methionine dependency such that their proliferation is impaired in growth media in which methionine is replaced by homocysteine. We showed that oncogenic PIK3CA and decreased expression of SLC7A11, a gene that encodes a cystine transporter also known as xCT, correlated with increased methionine dependency in breast cancer cells. Oncogenic PIK3CA was sufficient to confer methionine dependency to mammary epithelial cells, partly by decreasing cystine uptake through the transcriptional and posttranslational inhibition of xCT. Manipulation of xCT activity altered the proliferation of breast cancer cells in methionine-deficient, homocysteine-containing media, suggesting that it functionally contributed to methionine dependency. We propose that concurrent with decreased cystine uptake through xCT, PIK3CA mutant cells use homocysteine through the transsulfuration pathway to synthesize cysteine. Consequently, less homocysteine is available to produce methionine, contributing to methionine dependency. These results indicate that oncogenic PIK3CA alters methionine and cysteine utilization, partly by inhibiting xCT to contribute to the methionine dependency phenotype in breast cancer cells.
INTRODUCTION
In the past decade, there has been a resurgence of interest in elucidating how metabolism is altered in cancer cells, with the goal of identifying cancer-associated metabolic dependencies that can be exploited for cancer therapy (1) . Metabolic differences between cancerous and normal cells often involve differential utilization of key "junction" metabolites. For example, one aspect of the Warburg effect is the preferential usage of glycolysis-derived pyruvate to generate lactate in cancer cells, whereas in normal cells, pyruvate is primarily directed toward the tricarboxylic acid cycle. From a therapeutic standpoint, differences in how cancer cells regulate the fate of key metabolites may potentially provide a means of targeting these metabolic junctions for treatment.
Homocysteine (Hcy) is a key junction metabolite that lies at the nexus of two pathways involved in methionine (Met) and cysteine (Cys) metabolism. High concentrations of Hcy are toxic to cells, and medical disorders known as hyperhomocysteinemia and homocystinuria are characterized by the accumulation of Hcy in the blood, leading to various symptoms, such as stroke, vascular diseases, and intellectual disabilities (2) . Therefore, cells must metabolize Hcy primarily through two different pathways: The methionine cycle and the transsulfuration pathway (Fig. 1A) . In the methionine cycle, Hcy is methylated to produce Met, an essential amino acid critical for cell growth and function. In addition to contributing to protein synthesis, Met is a precursor for the generation of S-adenosylmethionine, which, as the principal methyl group donor, is critical for various cellular methylation reactions (3) . S-adenosylhomocysteine is generated in the process and subsequently converted into Hcy, which is then used to regenerate Met to complete the cycle. Alternatively, Hcy can be metabolized through the transsulfuration pathway to synthesize the amino acid Cys, which is involved in multiple cellular antioxidant systems, such as the synthesis of glutathione (4) . Depending on cellular demand, Hcy can be directed either toward the methionine cycle to increase methylation potential or through the transsulfuration pathway to contribute to antioxidant metabolism.
In the context of cancer, the Hcy junction has been implicated in a cancer-associated metabolic vulnerability known as "methionine dependency," in which a majority of cancer cells cannot proliferate in growth media in which Met is replaced by its precursor Hcy (Met − Hcy + media). By contrast, most normal, nontumorigenic cells, such as fibroblasts and epithelial cells, are not methionine-dependent and can proliferate in Met − Hcy + media (5) (6) (7) . This phenotype has been demonstrated for various malignant cell lines and for patient tumors grown in primary culture from multiple cancers, including breast, bladder, colon, glioma, kidney, melanoma, and prostate cancer (8) (9) (10) (11) (12) (13) . Given these observations, methionine restriction has been proposed as a strategy for treating cancer, a notion that is supported by several preclinical models. For example, in animal models of various cancers, including rhabdomyosarcoma, Yoshida's sarcoma, hepatoma, and colorectal cancer, methionine-restricted diets inhibit tumor growth, prevent metastases, and extend survival (14) (15) (16) (17) . Other studies suggest that the enzyme methioninase, which degrades methionine, may be used pharmacologically to systemically deplete methionine levels to exert antitumor effects (18) (19) (20) (21) . Finally, preclinical and clinical studies have indicated that methionine restriction can act synergistically with chemotherapeutic agents to effectively treat tumors (22) (23) (24) (25) (26) .
Despite these promising results, one critical concern is that complete and prolonged systemic depletion of methionine may be toxic and even lethal in humans (14, 27, 28) . One challenge in more effectively exploiting methionine dependency in cancer treatment is that the mechanisms underlying this phenotype remain elusive. A few studies have evaluated the role of certain metabolic enzymes involved in methionine metabolism, especially methionine synthase (MTR), which converts Hcy to Met, and methylthioadenosine phosphorylase (MTAP), which is involved in the methionine salvage pathway (29) (30) (31) (32) (33) (34) (35) . Although these enzymes have been associated with methionine dependency, the exact metabolic alterations that are causally responsible for conferring methionine dependency have not been determined. Here, we provide evidence that oncogenic PIK3CA is sufficient to confer methionine dependency to mammary epithelial cells, partly by decreasing cystine (Cys 2 ) uptake through the transcriptional and posttranslational inhibition of xCT, a Cys 2 transporter encoded by SLC7A11.
RESULTS

Methionine dependency varies across different breast cancer cell lines
To study methionine dependency in breast cancer, we screened 13 breast cancer cell lines for their ability to proliferate in Met − Hcy + media (Fig. 1B) . On the basis of their proliferative capacities, we segregated the cell lines into three groups: Group A cells proliferated; group B cells did not proliferate, at least over the 4 days of the experiment; and group C cells died when cultured in Met − Hcy + media. To quantify the differences in methionine dependencies across the cell lines, we used these proliferation curves to calculate a Met − Hcy + growth rate for each cell line, again observing a segregation into the three groups (Fig. 1C) .
Differences in basal proliferation rates may potentially explain the observed range of methionine dependencies, because more proliferative cells may require more methionine for growth and therefore be more methionine-dependent. However, we did not find a significant correlation between the Met − Hcy + growth rates of the cell lines and their doubling times in regular growth media (Fig. 1D) . Therefore, the range of methionine dependencies across the cell lines was not likely to be simply due to differences in basal proliferative capacity.
Oncogenic PIK3CA is sufficient to confer methionine dependency to mammary epithelial cells We noticed that many of the most methionine-dependent breast cancer cell lines harbor a PIK3CA genomic mutation (Table 1) , particularly two of the three group C cell lines (MCF7 and T47D) and the most methionine-dependent group B cell line (SUM-159). Notably, PTEN genomic mutations also tended to cluster toward the group B and C cell lines with negative Met − Hcy + growth rates ( Fig. 1C and Table 1 ). However, drawing a correlation between PTEN protein abundance and methionine dependency will require a quantitative analysis of PTEN protein abundance in these cell lines. All group A cell lines were negative for PTEN abundance at the protein level (Table 1) , weakening the association of PTEN mutational status with methionine dependency. Given that two of the three group C cell lines harbored a PIK3CA mutation, we focused on assessing whether oncogenic PIK3CA might contribute to the methionine dependency phenotype. (Fig. 2C) . Together, these results indicate that oncogenic PIK3CA is sufficient to confer methionine dependency to mammary epithelial cells.
Oncogenic PIK3CA inhibits cystine uptake through xCT We reasoned that oncogenic PIK3CA may rewire cellular metabolism to confer methionine dependency, perhaps by altering the expression of genes involved in methionine and cysteine metabolism. To identify these candidate genes, we used published RNA expression data (36) to correlate the expression of a selected set of methionine and cysteine metabolism genes (listed in the Materials and Methods) to the Met − Hcy + growth rates of our panel of cell lines (data file S1). Within this analysis, two genes were significantly correlated: Increased methionine dependency was associated with high MAT1A (which encodes methionine adenosyltransferase 1A) expression and low SLC7A11 (which encodes solute carrier family 7 member 11) expression (Fig. 3A  and fig. S2 , A and B). Next, we asked whether these transcriptional changes were also observed in the methionine-dependent PIK3CA mutant MCF10A cells. SLC7A11 expression was significantly lower in the PIK3CA mutant cells, whereas there was no significant difference in MAT1A expression (Fig. 3B) . Consistently, SLC7A11 expression trended toward lower expression in the methionine dependent group C breast cancer cell lines, relative to the group A cell lines (Fig. 3C) . Immunoblotting for endogenous SLC7A11 in two cell lines each from groups A to C revealed that the group C cell lines MDA-MB-468 and MCF7 had lower SLC7A11 protein abundance compared to the group A cell lines HCC38 and SUM-149 (Fig. 3D) . SLC7A11, also known as xCT, is a cystine-glutamate antiporter that exchanges intracellular glutamate to take up extracellular cystine (Cys 2 ), which is the oxidized form of Cys (37) . Consistent with reduced xCT expression, PIK3CA mutant cells exhibited a significantly decreased rate of Cys 2 uptake (Fig. 3E) . (50) and (65) . ‡Reported in ref. (66) .
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In addition to transcriptional regulation, we also noted that multiple mass spectrometry-based studies have identified xCT to be phosphorylated on Ser 26 , and the amino acid sequence surrounding this phospho-site is similar to the AKT substrate motif RxRxxS/T, with an Arg at the −3 position (Fig. 4A ; www.phosphosite.org). To determine whether xCT Ser 26 was phosphorylated downstream of phosphoinositide 3-kinase (PI3K), we stably expressed both WT and the S26A mutant of a C-terminally hemagglutinin (HA)-FLAG-tagged xCT in were then immunoblotted for the indicated proteins (data are representative of three independent experiments). PARP, poly(ADP-ribose) polymerase. All error bars represent SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 by a two-sided Student's t test. MCF10A WT or PIK3CA(H1047R) cells. We then serum-starved these cells, and by immunoprecipitating xCT with an HA antibody and immunoblotting with an antibody recognizing the p-RxxS/T phospho-motif, we found that xCT was constitutively phosphorylated in the PIK3CA(H1047R) cells. The S26A mutation abolished phosphorylation, indicating that xCT was phosphorylated at Ser 26 downstream of the PI3K pathway (Fig. 4B) . We also stimulated serumstarved WT MCF10A cells expressing xCT-HA-FLAG with insulin to activate PI3K. xCT phosphorylation was stimulated by insulin within 5 to 10 min and was attenuated by 30 to 60 min (Fig. 4C ). The kinetics of xCT phosphorylation was similar to that of a canonical AKT substrate, PRAS40 (Fig. 4C ), suggesting that AKT may be the kinase responsible for xCT phosphorylation. Phosphorylation of xCT in MCF10A PIK3CA(H1047R) mutant cells was abolished by the PI3K inhibitor GDC-0941, the AKT inhibitors GDC-0068 and MK2206, and the mechanistic target of rapamycin (mTOR) catalytic inhibitor Torin1. By contrast, the mTORC1/S6K inhibitor rapamycin did not affect xCT phospho rylation (Fig. 4D) . Moreover, in MCF10A cells, we detected phospho rylation of endogenous xCT upon insulin stimulation, which was inhibited by both PI3K and AKT inhibitors ( fig. S3 ). These results suggest that xCT is phosphorylated either by AKT or a kinase downstream of AKT that is not mTORC1. To further confirm that AKT was the responsible kinase, we conducted in vitro kinase assays with immunoprecipitated xCT and recombinant AKT1 (Fig. 4E) . In vitro assays indicated that AKT1 phosphorylated xCT, but not xCT(S26A), demonstrating that AKT can directly phosphorylate xCT at Ser 26 in vitro. Finally, to determine the functional consequence of xCT Ser 26 phosphorylation, we measured glutamate secretion to assay xCT activity. We found that MCF10A cells expressing xCT(S26A) secreted more glutamate than cells expressing WT xCT (Fig. 4F) , suggesting that phosphorylation of xCT at Ser 26 inhibits its cystine transport activity. Together, the results above support a model in which oncogenic PIK3CA inhibits xCT activity through two mechanisms: (i) transcriptional inhibition of SLC7A11 expression and (ii) AKT-mediated phosphorylation of xCT at Ser 26 .
xCT functionally contributes to the methionine dependency phenotype The above results indicated that oncogenic PIK3CA decreased Cys 2 uptake through both the transcriptional and posttranslational inhibition of xCT, and this metabolic phenotype was correlated with increased methionine dependency. On the basis of this model, we next explored the potential role of the inhibition of xCT and Cys 2 uptake in contributing to the methionine dependency induced by oncogenic PIK3CA.
We hypothesized that xCT overexpression may reverse methionine dependency because PIK3CA mutant MCF10A cells expressed lower amounts of xCT. We found that MCF10A PIK3CA(H1047R) cells overexpressing xCT proliferated in both normal media containing Met and in Met − Hcy + media (Fig. 5A and fig. S4A ). Similarly, xCT overexpression restored the viability of these PIK3CA mutant cells in Met − Hcy + media, as measured with a PI-based cell death assay (Fig. 5B) . Together, these results indicate that at least in the context of MCF10A cells, xCT is a mediator of the methionine dependency induced by oncogenic PIK3CA, because its expression was sufficient to rescue the methionine dependency of the PIK3CA mutant cells.
We also assessed whether manipulation of xCT expression and activity affects the methionine dependency of our panel of cell lines (Fig. 1B) . Because group A cells, which proliferated in Met − Hcy + media, expressed higher amounts of xCT (Fig. 3, A and C) , then inhibition of Cys 2 uptake in these cells should confer the methionine dependency phenotype. We found that removal of Cys 2 from the growth media to inhibit Cys 2 uptake led to proliferation of each of the group A cell lines in either Met (SSA), for 4 days, and the proliferation of cells was determined using the SRB assay (n = 3 to 4 biologically independent replicates). (E) Cells were grown in Met − Hcy + media for 6 days, and the proliferation of cells was determined using the SRB assay (n = 3 biologically independent replicates). All error bars represent SEM. *P < 0.05 by a two-sided Student's t test.
# P < 0.05 by a paired t test.
in Met − Hcy + media is least affected by Cys 2 deprivation or SSA (Fig. 5,  C and D) . Together, these results suggest that Cys 2 uptake is required for the group A cell lines to regulate Hcy utilization in a manner that permits proliferation in the Met − Hcy + media. Conversely, the methionine-dependent group C cell lines expressed lower amounts of xCT, and we hypothesized that xCT overexpression may reverse their methionine dependency. Although the rescue was not as robust as in MCF10A cells (Fig. 5, A and B) , xCT expression did modestly improve the survival of the group C cells in Met − Hcy + media, particularly for T47D cells, and to a lesser extent, for MCF7 cells (although this rescue was reproducible, it was small and not statistically significant) (Fig. 5E ). This result suggests that although xCT may be required for the proliferation of group A cells in Met − Hcy + media, xCT expression was only partially sufficient in reversing the methionine dependency of two of the three group C cells. Therefore, although xCT may partially contribute to methionine dependency in the context of these two cell lines, it is likely that other factors are also involved. Overall, these analyses in the group A and C cell lines suggest that xCT is at least one of the mediators of the methionine dependency phenotype because manipulation of its activity or expression modulated the degree to which cells can grow in Met − Hcy + media.
Oncogenic PIK3CA alters methionine utilization through the transsulfuration pathway Finally, we asked whether oncogenic PIK3CA alters methionine metabolism and the ability of cells to use Hcy to either regenerate Met through the methionine cycle or synthesize Cys through the transsulfuration pathway. We hypothesized that because oncogenic PIK3CA decreased Cys 2 uptake in MCF10A cells (Fig. 3E) (Fig. 6B) . After 1 hour of labeling, a time point at which steady-state labeling had not been reached, we found greater incorporation of the 13 C label into [M+4] cystathionine in the PIK3CA mutant MCF10A cells relative to empty vector-transfected cells (Fig. 6C ), which together with increased steady-state cystathionine pool sizes (Fig. 6A) , suggests an increased flux through the transsulfuration pathway. We then provided these cells with [U- cystathionine was inhibited by GDC-0941, indicating that transsulfuration pathway activity depended on PI3K signaling (Fig. 6D) . Furthermore, concurrent with a decrease in [M+4] cystathionine induced by GDC-0941, PI3K inhibition also increased labeling in C 5 ]-methionine for 24 hours and treated with or without 1 M GDC-0941 (n = 3 biologically independent replicates). All error bars represent SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 by a two-sided Student's t test.
[M+4] methionine, suggesting that activation of PI3K directs the utilization of Met through Hcy toward the transsulfuration pathway and away from remethylation through the methionine cycle to regenerate Met (Fig. 6E) . Notably, inhibition of [M+4] cystathionine by GDC-0941 was more robust in the empty vector-transfected cells relative to the PIK3CA(H1047R)-expressing cells (Fig. 6, D and E) , which reflected the stronger inhibition of PI3K signaling by GDC-0941 in the empty vector-transfected cells under these conditions ( fig. S5 ). This result therefore further suggests a correlation between PI3K activity and conversion of Hcy to cystathionine. Together, these results are consistent with a model in which cells with oncogenic PIK3CA cannot proliferate in Met − Hcy + media because the supplemented Hcy is used for transsulfuration and is not efficiently remethylated to produce Met.
DISCUSSION
Here, we demonstrated that in breast cancer cell lines, oncogenic PIK3CA was associated with methionine dependency, a cancerassociated metabolic dependency in which cells cannot proliferate in Met − Hcy + media. In mammary epithelial MCF10A cells, oncogenic PIK3CA was sufficient to confer methionine dependency through a PI3K-induced decrease in Cys 2 uptake mediated by both transcriptional and posttranslational inhibition of the Cys 2 transporter xCT. xCT at least partially mediated the methionine dependency phenotype because manipulation of xCT activity or expression modulated the methionine dependency of breast cancer cells. Together, our data provide evidence to link oncogenic PIK3CA and xCT-mediated Cys 2 uptake with methionine dependency, a mechanistically poorly understood cancer-associated metabolic dependency.
The mechanism by which oncogenic PIK3CA decreases xCT expression remains an open question. We have previously reported that expression of an oncogenic AKT mutation in MCF10A cells also decreases xCT expression (39) . The transcription factor Nrf1 has been reported to act as a repressor of xCT expression (40) , and mTORC1 is an activator of Nrf1 (41) . Because mTORC1 signals downstream of PI3K, one potential hypothesis is that oncogenic PIK3CA may decrease xCT expression through the mTORC1-mediated activation of Nrf1.
Notably, posttranslational regulation of xCT downstream of PI3K resulting in phosphorylation of Ser 26 and inhibition of Cys 2 uptake has been previously reported (42) , and as such, is consistent with the results presented here. Gu et al. identified mTORC2, but not AKT, as the kinase responsible for phosphorylation of xCT at Ser 26 in cells. However, consistent with our data, they also showed that AKT can potentially phosphorylate xCT with in vitro kinase assays (42) . The motif surrounding Ser 26 in xCT conforms only partially to both the mTOR (43, 44) and the AKT consensus motifs (45, 46) , and the responsible kinase in vivo may therefore conceivably depend on distinct cellular contexts. In our system, xCT phosphorylation was robustly inhibited by the AKT inhibitors GDC-0068 and MK2206 but not the mTORC1 inhibitor rapamycin, suggesting that xCT Ser 26 may be phosphorylated by either AKT or a downstream kinase that is not mTORC1. However, an alternative explanation that could reconcile our results with those of Gu et al. (42) is the positive feedback loop from AKT to mTORC2 (47) . If this feedback loop is functional in the cells used in our study, then AKT inhibitors would impair activation of mTORC2 by AKT, leaving open the possibility that mTORC2 could be the responsible kinase for xCT phosphorylation, at least under these conditions. Regardless, because both AKT and mTOR catalytic inhibitors impair xCT phosphorylation, our data indicate that both mTORC2 and AKT are equally required for xCT phosphorylation.
xCT-mediated Cys 2 uptake and the transsulfuration pathway constitute two main mechanisms by which a cell can obtain Cys. Our [U- 13 C 5 ]-methionine tracing data suggested that concurrent with decreased Cys 2 uptake through xCT, PIK3CA mutant MCF10A cells used Met-derived Hcy for synthesizing Cys through the transsulfuration pathway, as opposed to remethylating Hcy to regenerate Met. These results are consistent with a model in which the ability of a cell to take up exogenous sources of Cys through xCT may influence whether that cell synthesizes Cys intracellularly through Hcy transsulfuration. In turn, the degree to which a cell uses the transsulfuration pathway for Cys may then affect the regulation of the Hcy junction by modulating how efficiently Hcy is remethylated through the methionine cycle to produce Met. Therefore, cells with more transsulfuration pathway activity would be more methionine-dependent, because less Hcy flux is devoted toward the methionine cycle to generate sufficient Met to continue proliferating in Met − Hcy + media. In support of this model, group A cells, including WT MCF10A cells, expressed higher amounts of xCT and may therefore use the transsulfuration pathway less to obtain Cys. As a result, in Met − Hcy + media, Hcy can be devoted toward Met production through the methionine cycle to restore sufficient Met levels for proliferation. Conversely, in group C cells, including PIK3CA mutant MCF10A cells, Cys 2 uptake was decreased through inhibition of xCT expression and activity by oncogenic PI3K. These cells therefore used the transsulfuration pathway to a greater extent to obtain Cys, resulting in less Hcy-to-Met conversion, impaired proliferation, and cell death in Met − Hcy + media. Notably, MDA-MB-468 cells, a group C cell line, exhibit increased transsulfuration pathway activity in Met − Hcy + media, which is consistent with our hypothesis (48) . Finally, manipulation of xCT activity or expression may modulate the methionine dependency phenotype by altering the dependence of cells on transsulfuration-derived Cys, thereby influencing the relative diversion of Hcy into the methionine cycle compared to the transsulfuration pathway.
Although xCT contributes to methionine dependency, it is unlikely to be the only functional mediator of this phenotype. In the context of the group C breast cancer cell lines, xCT overexpression was only partially sufficient in reversing their methionine dependency. Moreover, it is important to note that although our data provides evidence for oncogenic PIK3CA mutations promoting methionine dependency, the correlation between methionine dependency and alterations within various nodes of the PI3K pathway, in general, was not as strong. For example, in our analysis of our panel of breast cancer cell lines, although genomic mutations in both PIK3CA and PTEN clustered toward cell lines with negative Met − Hcy + growth rates, all of the group A cell lines are also negative for PTEN protein abundance. On one hand, this observation may reflect the idea that genetic alterations at different nodes of the PI3K pathway may not function equivalently, as has been demonstrated for other phenotypes such as drug sensitivity and organoid growth (49) (50) (51) , and may provide a rationale for testing how PTEN alterations contribute to methionine dependency in an isogenic system. However, this observation also points toward the likelihood that other genes may more strongly modulate the capacity to proliferate in Met − Hcy + media. Other methods, such as focused single-guide RNA or complementary DNA overexpression screens targeting genes involved in Met and Cys metabolism, may be used to identify other factors that modify the methionine dependency phenotype.
Note also that the transsulfuration pathway is restricted to certain normal tissues in an organism, such as the liver, pancreas, and kidney (52) . However, this pathway is also active in various cancer cells, including breast cancer cells (48, (53) (54) (55) . Moreover, the transsulfuration pathway can serve as a source of Cys for glutathione synthesis, and it is possible that the regulation of this pathway by oncogenic PIK3CA may support the PI3K-mediated stimulation of glutathione synthesis (39) . It would also be interesting to explore whether a subset of cancer cells with transsulfuration pathway activity depend on this pathway to maintain their cellular Cys pools for growth and survival. If so, the transsulfuration pathway could be a potential therapeutic target for this subset of cancer cells.
In summary, we have identified a junction in metabolism that appears to be regulated differently in a subset of breast cancer cells: The metabolism of Hcy in either the methionine cycle to produce Met or in the transsulfuration pathway to synthesize Cys. The utilization of Hcy through these two pathways, which is partly altered by oncogenic PIK3CA and the degree to which cells depend on Cys 2 uptake through xCT, then contributes to the methionine dependency phenotype. This work provides another example of the role of the PI3K pathway in mediating metabolic reprogramming in various cancers (56) . In addition, xCT alters the utilization of other nutrients by cancer cells. For example, xCT overexpression results in higher glutamate export, rendering cancer cells more sensitive to glucose starvation (57, 58) . Increased xCT-dependent cystine uptake and glutamate release also leads to dependence by some cancer cell lines on glutamine anaplerosis for proliferation, which results in greater sensitivity to glutaminase inhibitors (59, 60) . By showing that PI3K-mediated regulation of xCT also influences methionine and cysteine metabolism in breast cancer cells, our work adds to the body of evidence describing how xCT alters nutrient utilization by cancer cells to modulate their dependency on different nutrients for survival.
MATERIALS AND METHODS
Cell lines
Cell lines were obtained from the American Type Culture Collection and authenticated using short tandem repeat profiling. MCF10A cells with a knock-in PIK3CA(H1047R) mutation were obtained from Horizon Discovery. No cell lines used in this study were found in the database of commonly misidentified cell lines, which is maintained by the International Cell Line Authentication Committee and National Center for Biotechnology Information BioSample. MCF10A cells were maintained in Dulbecco's modified Eagle's medium (DMEM)/ Ham's F12 (CellGro) supplemented with 5% equine serum (CellGro), insulin (10 g/ml) (Life Technologies), hydrocortisone (500 ng/ml) (Sigma-Aldrich), epidermal growth factor (EGF; 20 ng/ml) (R&D Systems), and cholera toxin (100 ng/ml) (Sigma-Aldrich). MDA-MB-231, MDA-MB-468, and MCF7 cells were maintained in DMEM (CellGro) supplemented with 10% fetal bovine serum (FBS) (Gemini). T47D and BT549 cells were maintained in RPMI 1640 (CellGro) supplemented with 10% FBS (Gemini) and insulin (10 g/ml) (Life Technologies). HCC38, HCC70, HCC1143, HCC1806, and ZR-75-1 cells were maintained in RPMI 1640 (CellGro) supplemented with 10% FBS (Gemini). SKBR3 cells were maintained in McCoy's 5A (CellGro) supplemented with 10% FBS (Gemini). SUM149 and SUM159 cells were maintained in Ham's F12 (CellGro) supplemented with insulin (5 g/ml) (Life Technologies), hydrocortisone (1 g/ml) (SigmaAldrich), and 5% FBS (Gemini). Cells were passaged for no more than 6 months and routinely assayed for mycoplasma contamination.
Met
+
Hcy
− and Met − Hcy + media DMEM lacking glutamine, pyruvate, methionine, and cystine was obtained from Gibco and was supplemented as necessary with 2 mM glutamine (Gibco), 0.2 mM l-methionine (Sigma-Aldrich), 0.2 mM l-cystine (Sigma-Aldrich), 0.1 mM l-homocystine (Sigma-Aldrich), and 10% dialyzed FBS (CellGro). For MCF10A cells, the medium was also supplemented with 5% dialyzed FBS (CellGro), insulin (10 g/ml) (Life Technologies), hydrocortisone (500 ng/ml) (Sigma-Aldrich), EGF (20 ng/ml) (R&D Systems), and cholera toxin (100 ng/ml) (Sigma-Aldrich).
Growth factors and inhibitors
For insulin stimulation, cells were serum-starved for 20 to 24 hours and stimulated with 100 nM insulin (Life Technologies). Inhibitors were used as follows: 1 M GDC-0941 (LC Laboratories), 1 M GDC-0068 (Active Biochem), 1 M MK2206 (Selleck Chemicals), 100 nM rapamycin (Cayman Chemicals), 1 M Torin 1 (Tocris), and 1 mM SSA (Sigma-Aldrich). Plasmids pJP1520-HA-GFP, pJP1520-HA-PIK3CA WT, pJP1520-HA-PIK3CA (E545K), and pJP1520-HA-PIK3CA(H1047R) were gifts from A.S. Baldwin (61). pENTR223-SLC7A11 was obtained from the DanaFarber/Harvard Cancer Center DNA Resource Core, and SLC7A11 was subcloned into the pHAGE-C-HA-FLAG lentiviral expression vector (W. Harper, Harvard Medical School). The SLC7A11 S26A mutation was generated by site-directed mutagenesis (Qiagen). pLKO.1 vector was used as empty vector control.
Antibodies
Immunoblotting and immunoprecipitation
Cells were washed with phosphate-buffered saline (PBS) at 4°C and lysed in radioimmunoprecipitation assay buffer ]1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 50 mM tris-HCl (pH 7.5), proteinase inhibitor cocktail, 50 nM calyculin, 1 mM sodium pyrophosphate, and 20 mM sodium fluoride] for 15 min at 4°C. Cell extracts were precleared by centrifugation at 14,000 rpm for 5 to 10 min at 4°C, and protein concentration was measured with the Bio-Rad DC protein assay. For HA-tag immunoprecipitations, lysates were incubated with 10 l of HA beads (Thermo Fisher Scientific) for 3 hours. Beads were then washed four times with NETN buffer [20 mM trisHCl (pH 8), 100 mM NaCl, 0.5% NP-40, and 1 mM EDTA] and one time with PBS before elution with SDS sample buffer. For endogenous xCT immunoprecipitations, lysates were collected as described above and incubated with anti-xCT primary antibody for 2 hours, followed by 2 more hours with 20 l of protein A beads. Lysates were then resolved on acrylamide gels by SDS-polyacrylamide gel electrophoresis and transferred electrophoretically to nitrocellulose membrane (BioRad) at 100 V for 90 min. The blots were blocked in tris-buffered saline (TBST) buffer [10 mM tris-HCl (pH 8), 150 mM NaCl, and 0.2% Tween 20] containing 5% (w/v) nonfat dry milk for 1 hour and then incubated with the specific primary antibody diluted in blocking buffer at 4°C overnight. Membranes were washed three times in TBST and incubated with HRP-conjugated secondary antibody for 1 hour at room temperature. For endogenous xCT immunoprecipitations, a conformation-specific secondary antibody conjugated to HRP (mouse anti-rabbit-HRP; Cell Signaling Technology, #5127) was used to facilitate the detection of endogenous xCT phosphorylation. Membranes were washed three times and developed using enhanced chemiluminescence substrate (EMD Millipore).
In vitro kinase assay
Human embryonic kidney-293T expressing empty vector, pHAGE-C-HA-FLAG xCT, or pHAGE-C-HA-FLAG xCT(S26A) were serumstarved for 20 hours and then treated with 1 M MK2206 for 30 min before collection of lysates and HA-xCT immunoprecipitation, as described above. Immunoprecipitated samples were incubated at 30°C for 1 hour in the presence of kinase assay reaction buffer (Cell Signaling Technology, #9802), adenosine triphosphate (200 M), and dithiothreitol (2mM), with or without 0.5 g of active glutathione S-transferase (GST)-AKT1 (Sigma-Aldrich, #SRP5001). The reaction was stopped by adding 12 l of 6× SDS loading buffer. Samples were resolved by Western blotting, as described above. Two hundred microliters of media were used per well on a 96-well plate, and 1 ml of media was used per well on a 24-well plate. Cell number was measured at the indicated time points using sulforhodamine B staining, as previously described (62) .
Proliferation assays
PI viability assay
Cell viability was assayed with a PI-based plate-reader assay, as previously described (63) . Briefly, cells in 96-well plates were treated with a final concentration of 30 M PI for 60 min at 37°C. The initial fluorescence intensity was measured in a SpectraMax M5 (Molecular Devices) at 530-nm excitation/620-nm emission. Digitonin was then added to each well at a final concentration of 600 M. After incubating for 30 min at 37°C, the final fluorescence intensity was measured. The fraction of dead cells was calculated by dividing the backgroundcorrected initial fluorescence intensity by the final fluorescence intensity. Viability was calculated by (1 -fraction of dead cells). Quantitative real-time polymerase chain reaction Total RNA was isolated with the NucleoSpin RNA Plus (MACHEREY-NAGEL) according to the manufacturer's protocol. Reverse transcription was performed using the TaqMan Reverse Transcription Kit (ThermoFisher Scientific). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using an ABI Prism 7700 sequence detector. SLC7A11 primer: sense, 5′-TGCTGGGCTGATTT-ATCTTCG-3′, antisense, 5′-GAAAGGGCAACCATGAAGAGG-3′; MAT1A primer: sense, 5′-ATGCTACCGACGAGACAGAG-3′, antisense, 5′-GATGACGATGGTGTGGATGC-3′; 18S primer: sense, 5′-GTAACCCGTTGAACCCCATT-3′, antisense, 5′-CCATCCAA-TCGGTAGTAGCG-3′. PCR was carried out in triplicate. Quantification of mRNA expression was calculated by the CT method with 18S ribosomal RNA as the reference gene. C]-Cystine, 110 mCi/mmol; PerkinElmer) was then added to the media at 0.9 M for 5 min at 37°C. Uptake was terminated by rinsing the cells two times with ice-cold PBS. Cells were then lysed with 400 l of 0.2 M NaOH containing 1% SDS, and lysates were centrifuged at 13,000 rpm for 5 min at room temperature. Two hundred fifty microliters of the lysate was mixed with 5 ml of scintillation cocktail (Ultima Gold, PerkinElmer), and radioactivity was measured using a scintillation counter. The remaining lysate was used for protein determination by the Bio-Rad DC protein assay, and the scintillation count for each sample was normalized by protein concentration.
Growth rate and gene expression correlation analysis
Glutamate release rate MCF10A cells were seeded at 250,000 cells per well on a six-well plate. On the following day, the cells were washed twice with PBS, and 2 ml of Met + Hcy − media were placed in each well. One milliliter of media was immediately removed and centrifuged at 3000 rpm, and the supernatant was frozen for analysis. Cell number on the plate was also determined using the sulforhodamine B assay. One day later, medium was harvested and cell number was determined in the same manner. Glutamate concentrations in the media were measured by gas chromatography-mass spectrometry (GC-MS). Ten microliters of media was added to 10 l of isotopically labeled internal standards of amino acids (Cambridge Isotope Laboratory, MSK-A2-1.2), and this mixture was extracted in 300 l of ice-cold high-performance liquid chromatography (HPLC)-grade methanol (Sigma-Aldrich), vortexed for 10 min, and centrifuged at 15,000 rpm for 10 min. Two hundred eighty microliters of the supernatant was dried under nitrogen gas, and the remaining pellet was analyzed by GC-MS after methoxaminetert-butyldimethylsilyl derivatization, as previously described (59) . To calculate the glutamate release rate (picomoles per cell per day), changes in glutamate concentration were normalized to the integrated growth curve of each culture (number of cell·days during which glutamate was released), which was calculated by using the cell numbers at the initial day and day 1 counts to fit an exponential growth equation.
LC-MS/MS metabolomic profiling
Cells were maintained in the indicated growth media, and fresh medium was added 2 hours before the experiment. For metabolite extraction, medium was aspirated, and 80% (v/v) methanol at dry ice temperatures was added. Cells and the metabolite-containing supernatants were collected, and the insoluble material in lysates was centrifuged at 4000g for 5 min. The resulting supernatant was evaporated using a refrigerated SpeedVac. Samples were resuspended using 20-l HPLC grade water for MS. Ten microliters was injected and analyzed using a 5500 QTRAP hybrid triple quadrupole mass spectrometer (AB/Sciex) coupled to a Prominence UFLC HPLC system (Shimadzu) via selected reaction monitoring (SRM) of a total of 254 endogenous water soluble metabolites for steady-state analyses of samples. Some metabolites were targeted in both positive and negative ion mode for a total of 285 SRM transitions using positive/negative switching. Electrospray ionization voltage was +4900 V in positive ion mode and −4500 V in negative ion mode. The dwell time was 4 ms per SRM transition, and the total cycle time was 1.89 s. About 9 to 12 data points were acquired per detected metabolite. Samples were delivered to the MS via normal-phase chromatography using a 4.6-mm inside diameter × 10 cm Amide XBridge hydrophilic interaction liquid chromatography (HILIC) column (Waters Corp.) at 300 l/min. Gradients were run starting from 85% buffer B (HPLC grade acetonitrile) to 42% B from 0 to 5 min; 42 to 0% B from 5 to 16 min; 0% B was held from 16 to 24 min; 0 to 85% B from 24 to 25 min; and 85% B was held for 7 min to re-equilibrate the column. Buffer A was composed of 20 mM ammonium hydroxide/20 mM ammonium acetate (pH 9.0) in water/acetonitrile (95:5). Peak areas from the total ion current for each metabolite SRM transition were integrated using MultiQuant v2.0 software (AB/Sciex). For 13 C-labeled experiments, SRMs were created for expected 13 C incorporation in various forms for targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS). Data analysis was performed in MatLab. Metabolite total ion counts represent the normalized (by cellular protein content), integrated total ion current from a single SRM transition.
Isotope labeling
For labeling in MCF10A cells, DMEM lacking glutamine, pyruvate, methionine, and cystine were obtained from Gibco and supplemented with 2 mM glutamine (Gibco), 0.2 mM l-cystine (Sigma-Aldrich), 0.2 mM [U- 13 C 5 ]-l-methionine (Cambridge Isotope Labs), 5% dialyzed FBS (CellGro), insulin (10 g/ml) (Life Technologies), hydrocortisone (500 ng/ml) (Sigma-Aldrich), EGF (20 ng/ml) (R&D Systems), and cholera toxin (100 ng/ ml) (Sigma-Aldrich). Fresh unlabeled medium, with or without 1 M GDC-0941, was added to the cells 2 hours before labeling. Labeled medium, with or without 1 M GDC-0941, was then added to the cells, and cellular metabolites were extracted as described above at 1 and 24 hours.
Statistics and reproducibility
Sample sizes and reproducibility for each figure are denoted in the figure legends. Unless otherwise noted, all Western blots are representative of at least three biologically independent experiments. Statistical significance between conditions was assessed by two-tailed Student's t tests. All error bars represent SEM, and significance between conditions is denoted as *P < 0.05, **P < 0.01, and ***P < 0.001.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/10/510/eaao6604/DC1 Fig. S1 . Characterization of MCF10A cells stably expressing PIK3CA variants. 
